Verastem Oncology

Verastem Oncology is a biopharmaceutical company focused on developing treatments for patients with cancer, particularly those with mutations in the RAS family of genes. The company's pipeline includes the investigational drugs avutometinib and defactinib, which are being explored in clinical trials for their potential to improve outcomes for patients with difficult-to-treat cancers.